EGFR and neoplasm: Concurrent preclinical studies confirmed the limited impact on 18F-FDG uptake in EGFR-altered GBM tumor, suggesting this limitation may be due to inability of the EGFR TKI to robustly inhibit extracellular domain mutant EGFR signaling in GBM.